Journal of Cancer Research and Therapeutics Close
 

Figure 3: Inhibition of U-87 MG tumor growth by FL34 in the subcutaneously transplanted and orthotopic xenograft model. (a and b) The activity of FL34 was determined in the subcutaneously transplanted U-87 MG xenografts in nude mice. U-87 MG-bearing mice were randomly separated into four groups of five animals. One group received 20% PEG400 as a vehicle control; the other groups received 30.0 mg/kg temozolomide, or 15.0 or 30.0 mg/kg FL34 daily (FL34 14 times; temozolomide five times). The xenograft tumor volumes were measured. (a) Mean relative tumor volumes ± standard deviation at the indicated time points. (b) Corresponding U-87 MG tumors in the subcutaneously transplanted xenograft model. (c) Tumor volumes for U-87 MG cells in the orthotopic xenograft model. U-87 MG tumor-bearing animals receiving different treatments were assessed by MRI. There was a significant decrease in the tumor volume in mice treated with FL34 or temozolomide when compared with untreated mice. (d) T2 weighted images of U-87 MG glioma-bearing mice in situ. Each image was obtained from different mice from each treatment group. (di) representative control mouse (15 days following U-87 MG cells implantation); (dii) representative FL34-treated mouse (15 days following U-87 MG cells implantation)

Figure 3: Inhibition of U-87 MG tumor growth by FL34 in the subcutaneously transplanted and orthotopic xenograft model. (a and b) The activity of FL34 was determined in the subcutaneously transplanted U-87 MG xenografts in nude mice. U-87 MG-bearing mice were randomly separated into four groups of five animals. One group received 20% PEG400 as a vehicle control; the other groups received 30.0 mg/kg temozolomide, or 15.0 or 30.0 mg/kg FL34 daily (FL34 14 times; temozolomide five times). The xenograft tumor volumes were measured. (a) Mean relative tumor volumes ± standard deviation at the indicated time points. (b) Corresponding U-87 MG tumors in the subcutaneously transplanted xenograft model. (c) Tumor volumes for U-87 MG cells in the orthotopic xenograft model. U-87 MG tumor-bearing animals receiving different treatments were assessed by MRI. There was a significant decrease in the tumor volume in mice treated with FL34 or temozolomide when compared with untreated mice. (d) T2 weighted images of U-87 MG glioma-bearing mice <i>in situ.</i> Each image was obtained from different mice from each treatment group. (di) representative control mouse (15 days following U-87 MG cells implantation); (dii) representative FL34-treated mouse (15 days following U-87 MG cells implantation)